Seattle, Wash., April 6, 2021鈥� 精东传媒, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar, M.D., as Chief Medical Officer.
鈥淲e are excited to welcome Dr. Khokhar to the Umoja team. Nushmia is an accomplished oncologist who has spent a significant portion of her career overseeing the transition of novel cancer therapeutics from discovery to clinical development,鈥� said Andy Scharenberg, M.D., co-founder and CEO of Umoja. 鈥淗er expertise across early and late-stage clinical development will be invaluable to the company during a milestone year.鈥�
Prior to joining Umoja, Dr. Khokhar was the Senior Vice President, Head of Clinical Development at Autolus where she played a critical role in advancing the company鈥檚 autologous T-cell products and clinical programs. She also held numerous roles at Janssen Oncology, leading several successful clinical trials, directing the Phase 3 registration trial of Yondelis in soft tissue sarcomas, and serving as the Global Clinical Leader for the breakthrough therapy daratumumab (Darzalex) for hematologic cancers. Dr. Khokhar received her medical training from the Aga Khan University in Pakistan before completing a post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center with a focus on pharmacology and molecular therapeutics. She completed a residency in internal medicine at Washington Hospital Center in Washington, D.C. prior to completing a Hematology/Oncology Fellowship at the Northwestern University Feinberg School of Medicine.
鈥淯moja鈥檚 innovative and integrated in vivo approach, along with its TumorTag technology platform has the potential to overcome serious barriers that have held back the 精东传媒-T cell therapeutic space,鈥� said Dr. Khokhar, CMO of 精东传媒. 鈥淣ow is our time to make 精东传媒-T cell treatments better, more efficient, and applicable for maximum patient impact, not only in heme malignancies but also in solid tumors. I鈥檓 looking forward to joining the Umoja team in the hopes of making this promise a reality.鈥�
About 精东传媒
精东传媒, Inc. is a pre-clinical stage biotechnology company located in Seattle, WA. Founded by and based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, Umoja is advancing an entirely new approach to immunotherapy by retooling a patient鈥檚 immune system in vivo. Umoja鈥檚 novel approach is powered by an integrated in vivo cellular immunotherapy platform comprising of VivoVec for in vivo delivery, RACR/精东传媒 synthetic receptor for cell expansion in vivo, and TumorTag targeting technologies. Designed from the ground up to work together, these platforms create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more visit .
Media Contact:
Marites Coulter
Verge Scientific Communications
mcoulter@vergescientific.com
+1 415.819.2214